Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 3 » Issue 2

Smoking cessation therapy with varenicline

Authors Mohanasundaram UM, Chitkara R, Krishna G

Published 6 June 2008 Volume 2008:3(2) Pages 239—251

DOI https://doi.org/10.2147/COPD.S1848


Uma M Mohanasundaram, Rajinder Chitkara, Ganesh Krishna

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, CA, USA

Abstract: Smoking cessation is the only available intervention proven to halt progression of chronic obstructive pulmonary disease (COPD). The authors discuss the current existing treatment modalities and the role of a newly approved agent, varenicline, in promotion of smoking cessation. Varenicline is a novel agent that is a centrally acting partial nicotinic acetylcholine receptor agonist. It has both agonistic and antagonistic properties that together are believed to account for reduction of craving and withdrawal as well as blocking the rewarding effects of smoking. Its targeted mechanism of action, better efficacy and tolerability makes varenicline a useful therapeutic option for smoking cessation. In this article, we discuss presently available options for smoking cessation and review the literature on efficacy of varenicline.

Keywords: smoking cessation, varenicline, nicotine, receptors, therapy, COPD

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]